FLRT2 Functions As Tumor Suppressor Gene Inactivated by Promoter Methylation in Colorectal Cancer

Overview

Journal J Cancer

Specialty Oncology

Date 2020 Nov 16

PMID 33193897

Citations 10

Authors

Xiaohong Guo

Chao Song

Lei Fang

Min Li

Longtao Yue

Qing Sun

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is a leading cause of cancer death worldwide. Epigenetic alterations, especially DNA methylation, contribute to the initiation and progression of CRC. To identify novel methylated tumor suppressors in CRC, MethylRAD-Seq screening was performed. As the result, FLRT2 was found to be preferentially methylated. In the present study, we aimed to elucidate the epigenetic regulations and biological functions of FLRT2 in CRC. Significant FLRT2 hypermethylation was initially confirmed in CRC samples and cell lines. Meanwhile, downregulated expression of FLRT2 was observed in CRC, which is probably attributed to promoter methylation of FLRT2. Consistently, the expression of FLRT2 was restored after treatment with DNA demethylating agent 5-AZA. FLRT2 overexpression resulted in impaired cell viability and colony formation. Additionally, FLRT2 overexpression led to a reduction in cell migration and cell invasion. Furthermore, we also observed that FLRT2 induced cell cycle arrest. Mechanistically, these effects were associated with the downregulation of phosphor-AKT, phosphor-ERK, CDK2, Cyclin A, and MMP2, and upregulation of P21. Taken together, these results define a tumor-suppressor role of FLRT2 with epigenetic silencing in the pathogenesis of CRC. Moreover, FLRT2 promoter methylation may be a useful epigenetic biomarker for the prevention and treatment of CRC.

Citing Articles

TREMSUCS-TCGA - an integrated workflow for the identification of biomarkers for treatment success.

Balogh G, Jorge N, Dupain C, Kamal M, Servant N, Le Tourneau C J Integr Bioinform. 2024; 21(4).

PMID: 39654143 PMC: 11698617. DOI: 10.1515/jib-2024-0031.

The NEDD4/FLRT2 axis regulates NSCLC cell stemness.

Yang Y, Yan F, Gao Z, Li H, Wen S, Li Q Front Pharmacol. 2024; 15:1459978.

PMID: 39444619 PMC: 11496253. DOI: 10.3389/fphar.2024.1459978.

Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer.

Lee H, Saw A, Morris V, Napolitano S, Bristow C, Srinivasan S Clin Cancer Res. 2024; 30(22):5166-5179.

PMID: 39269307 PMC: 11829253. DOI: 10.1158/1078-0432.CCR-24-1166.

Evaluating Ovarian Cancer Chemotherapy Response Using Gene Expression Data and Machine Learning.

Amniouel S, Yalamanchili K, Sankararaman S, Jafri M BioMedInformatics. 2024; 4(2):1396-1424.

PMID: 39149564 PMC: 11326537. DOI: 10.3390/biomedinformatics4020077.

Proteogenomic characterization of primary colorectal cancer and metastatic progression identifies proteome-based subtypes and signatures.

Tanaka A, Ogawa M, Zhou Y, Namba K, Hendrickson R, Miele M Cell Rep. 2024; 43(2):113810.

PMID: 38377004 PMC: 11288375. DOI: 10.1016/j.celrep.2024.113810.

References

Karaulanov E, Bottcher R, Niehrs C . A role for fibronectin-leucine-rich transmembrane cell-surface proteins in homotypic cell adhesion. EMBO Rep. 2006; 7(3):283-90. PMC: 1456895. DOI: 10.1038/sj.embor.7400614. View

Javier Carmona F, Azuara D, Berenguer-Llergo A, Fernandez A, Biondo S, de Oca J . DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer. Cancer Prev Res (Phila). 2013; 6(7):656-65. DOI: 10.1158/1940-6207.CAPR-12-0501. View

Sveen A, Kopetz S, Lothe R . Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol. 2019; 17(1):11-32. PMC: 7577509. DOI: 10.1038/s41571-019-0241-1. View

Xicola R, Llor X . [DNA methylation defects in sporadic and hereditary colorectal cancer]. Gastroenterol Hepatol. 2012; 35(7):480-7. DOI: 10.1016/j.gastrohep.2012.01.010. View

Tsai H, Baylin S . Cancer epigenetics: linking basic biology to clinical medicine. Cell Res. 2011; 21(3):502-17. PMC: 3193419. DOI: 10.1038/cr.2011.24. View

Santin A, Zhan F, Cane S, Bellone S, Palmieri M, Thomas M . Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer. 2005; 92(8):1561-73. PMC: 2362016. DOI: 10.1038/sj.bjc.6602480. View

Haines B, Wheldon L, Summerbell D, Heath J, Rigby P . Regulated expression of FLRT genes implies a functional role in the regulation of FGF signalling during mouse development. Dev Biol. 2006; 297(1):14-25. DOI: 10.1016/j.ydbio.2006.04.004. View

Santin A, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E . Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 2004; 112(1):14-25. DOI: 10.1002/ijc.20408. View

Raskov H, Soby J, Troelsen J, Bojesen R, Gogenur I . Driver Gene Mutations and Epigenetics in Colorectal Cancer. Ann Surg. 2019; 271(1):75-85. DOI: 10.1097/SLA.0000000000003393. View

10.

Kim M, Lee J, Sidransky D . DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 2010; 29(1):181-206. DOI: 10.1007/s10555-010-9207-6. View

11.

Bestor T . The DNA methyltransferases of mammals. Hum Mol Genet. 2000; 9(16):2395-402. DOI: 10.1093/hmg/9.16.2395. View

12.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

13.

Lao V, Grady W . Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011; 8(12):686-700. PMC: 3391545. DOI: 10.1038/nrgastro.2011.173. View

14.

McCabe M, Lee E, Vertino P . A multifactorial signature of DNA sequence and polycomb binding predicts aberrant CpG island methylation. Cancer Res. 2009; 69(1):282-91. PMC: 2653261. DOI: 10.1158/0008-5472.CAN-08-3274. View

15.

Wei K, Xu Y, Tse H, Manolson M, Gong S . Mouse FLRT2 interacts with the extracellular and intracellular regions of FGFR2. J Dent Res. 2011; 90(10):1234-9. DOI: 10.1177/0022034511415272. View

16.

Stoffel E, Murphy C . Epidemiology and Mechanisms of the Increasing Incidence of Colon and Rectal Cancers in Young Adults. Gastroenterology. 2019; 158(2):341-353. PMC: 6957715. DOI: 10.1053/j.gastro.2019.07.055. View

17.

Tai-Nagara I, Yoshikawa Y, Numata N, Ando T, Okabe K, Sugiura Y . Placental labyrinth formation in mice requires endothelial FLRT2/UNC5B signaling. Development. 2017; 144(13):2392-2401. DOI: 10.1242/dev.149757. View

18.

Xu Y, Wei K, Kulyk W, Gong S . FLRT2 promotes cellular proliferation and inhibits cell adhesion during chondrogenesis. J Cell Biochem. 2011; 112(11):3440-8. DOI: 10.1002/jcb.23271. View

19.

Song L, Li Y . The Role of Stem Cell DNA Methylation in Colorectal Carcinogenesis. Stem Cell Rev Rep. 2016; 12(5):573-583. DOI: 10.1007/s12015-016-9672-6. View

20.

Donninger H, Bonome T, Radonovich M, Pise-Masison C, Brady J, Shih J . Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene. 2004; 23(49):8065-77. DOI: 10.1038/sj.onc.1207959. View